Bacteroides ovatus alleviates dysbiotic microbiota-induced intestinal graft-versus-host disease.

Autor:	Hayase E; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA., Hayase T; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA., Mukherjee A; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA., Stinson SC; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA., Jamal MA; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA., Ortega MR; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA., Sanchez CA; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA., Ahmed SS; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA., Karmouch JL; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA., Chang CC; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA., Flores II; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA., McDaniel LK; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA., Brown AN; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA., El-Himri RK; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA., Chapa VA; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA., Tan L; Metabolomics Core Facility, Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77230, USA., Tran BQ; Metabolomics Core Facility, Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77230, USA., Pham D; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA., Halsey TM; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA., Jin Y; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA., Tsai WB; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA., Prasad R; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA., Glover IK; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA., Ajami NJ; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA., Wargo JA; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA., Shelburne S; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA.; Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA., Okhuysen PC; Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA., Liu C; Department of Pathology, Yale School of Medicine, New Haven, Connecticut 06520, USA., Fowler SW; Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX 77030, USA.; Center for Comparative Medicine, Baylor College of Medicine, Houston, TX 77030, USA., Conner ME; Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX 77030, USA., Peterson CB; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA., Rondon G; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA., Molldrem JJ; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA., Champlin RE; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA., Shpall EJ; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA., Lorenzi PL; Metabolomics Core Facility, Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77230, USA., Mehta RS; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA., Martens EC; Department of Microbiology & Immunology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA., Alousi AM; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA., Jenq RR; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA.; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.; CPRIT Scholar in Cancer Research, Houston, Texas, USA.
Jazyk:	angličtina
Zdroj:	Research square [Res Sq] 2023 Jan 31. Date of Electronic Publication: 2023 Jan 31.
DOI:	10.21203/rs.3.rs-2460097/v1
Abstrakt:	Acute gastrointestinal intestinal GVHD (aGI-GVHD) is a serious complication of allogeneic hematopoietic stem cell transplantation, and the intestinal microbiota is known to impact on its severity. However, an association between treatment response of aGI-GVHD and the intestinal microbiota has not been well-studied. In a cohort of patients with aGI-GVHD (n=37), we found that non-response to standard therapy with corticosteroids was associated with prior treatment with carbapenem antibiotics and loss of Bacteroides ovatus from the microbiome. In a mouse model of carbapenem-aggravated GVHD, introducing Bacteroides ovatus reduced severity of GVHD and improved survival. Bacteroides ovatus reduced degradation of colonic mucus by another intestinal commensal, Bacteroides thetaiotaomicron , via its ability to metabolize dietary polysaccharides into monosaccharides, which then inhibit mucus degradation by Bacteroides thetaiotaomicron and reduce GVHD-related mortality. Competing Interests: Declaration of interests R.R.J. has served as a consultant or advisory board member for Merck, Microbiome DX, Karius, MaaT Pharma, LISCure, Seres, Kaleido, and Prolacta and has received patent license fee or stock options from Seres and Kaleido. E.J.S. has served as a consultant or advisory board member for Adaptimmune, Axio, Navan, Fibroblasts and FibroBiologics, NY Blood Center, and Celaid Therapeutics and has received patent license fee from Takeda and Affimed. E.H., M.A.J., J.L.K., and R.R.J. are inventors on a patent application by The University of Texas MD Anderson Cancer Center supported by results of the current study entitled, “Methods and Compositions for Treating Cancer therapy-induced Neutropenic Fever and/or GVHD.”
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu